.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Argus Health
Farmers Insurance
Accenture
Covington
McKinsey
Medtronic
Deloitte
Julphar
Express Scripts

Generated: December 13, 2017

DrugPatentWatch Database Preview

Atelvia Drug Profile

« Back to Dashboard

When do Atelvia patents expire, and when can generic versions of Atelvia launch?

Atelvia is a drug marketed by Apil and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-six patent family members in thirty-one countries.

The generic ingredient in ATELVIA is risedronate sodium. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.
Drug patent expirations by year for Atelvia

Pharmacology for Atelvia

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate

Medical Subject Heading (MeSH) Categories for Atelvia

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
ApilATELVIArisedronate sodiumTABLET, DELAYED RELEASE;ORAL022560-001Oct 8, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ApilATELVIArisedronate sodiumTABLET, DELAYED RELEASE;ORAL022560-001Oct 8, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
ApilATELVIArisedronate sodiumTABLET, DELAYED RELEASE;ORAL022560-001Oct 8, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ATELVIA

Drugname Dosage Strength RLD Submissiondate
risedronate sodiumDelayed-release Tablets35 mgAtelvia7/19/2011

Non-Orange Book Patents for Tradename: ATELVIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,409,614Low dosage forms of risedronate or its salts► Subscribe
8,535,718Dosage forms of bisphosphonates► Subscribe
8,409,615Low dosage forms of risedronate or its salts► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ATELVIA

Country Document Number Estimated Expiration
China104027323► Subscribe
Morocco28657► Subscribe
Russian Federation2381791► Subscribe
South Korea101070205► Subscribe
South Korea20070111551► Subscribe
South Korea101411117► Subscribe
European Patent Office2283825► Subscribe
New Zealand551118► Subscribe
Spain2349584► Subscribe
Israel186339► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Deloitte
Argus Health
Moodys
UBS
Healthtrust
Fuji
Chinese Patent Office
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot